Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2026-01-01 @ 1:45 AM
Study NCT ID:
NCT04893551
Status:
TERMINATED
Last Update Posted:
2023-04-20
First Post:
2021-05-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants
Sponsor:
BerGenBio ASA
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-02-25
Start Date Type:
ACTUAL
Primary Completion Date:
2022-06-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-06-27
Completion Date Type:
ACTUAL
First Submit Date:
2021-05-17
First Submit QC Date:
None
Study First Post Date:
2021-05-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-04-18
Last Update Post Date:
2023-04-20
Last Update Post Date Type:
ACTUAL